Sino Biopharmaceutical Launches New Anti-inflammatory Product in China

Sino Biopharmaceutical ( (HK:1177) ) has shared an announcement.

Sino Biopharmaceutical has announced the approval for marketing of its new product, Loxoprofen Sodium Cataplasms, by the National Medical Products Administration of China. This product is notable for being the only loxoprofen sodium cataplasm in China to have passed the Consistency Evaluation and been validated through clinical trials. It offers increased efficacy and safety compared to oral preparations, enhancing patient compliance with its once-daily dosage. The approval strengthens Sino Biopharmaceutical’s product pipeline in surgery and analgesia, providing more treatment options for patients.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a leading manufacturer in the pharmaceutical industry, focusing on modern topical and transdermal preparations. The company specializes in developing anti-inflammatory and analgesic products, with a strong presence in the Chinese market.

YTD Price Performance: -5.13%

Average Trading Volume: 2,288

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $6.9B

For a thorough assessment of 1177 stock, go to TipRanks’ Stock Analysis page.